Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10912991 | 0.84 | MEN1 (0.62) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9274995 | 0.82 | RAB9A (0.53) | HSD11B1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2648128 | 0.82 | HSD11B1 (0.54) | HSD11B1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL581464 | 0.82 | HSD11B1 (0.54) | HSD11B1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5954815 | 0.81 | HPGD (0.50) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5955284 | 0.81 | LOXL2 (0.48) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11824924 | 0.80 | HSD11B1 (0.53) | HSD11B1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1434608 | 0.80 | GSK3B (0.59) | HSD11B1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL8420333 | 0.80 | RAB9A (0.56) | HSD11B1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL30016132 | 0.80 | GSK3B (0.59) | HSD11B1NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083358-A1 | COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | FRATAGENE THERAPEUTICS S.R.L. (IT) | 2016-03-24 | — | — | US | disclosed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| EP-0653421-B1 | Process for preparing 2-cyanoimidazole compounds | ISHIHARA SANGYO KAISHA (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5552557-A | Process for preparing 2-cyanoimidazole compounds by reaction of an amino ketone compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1996-09-03 | — | — | US | disclosed |
| EP-0653421-A1 | Process for preparing 2-cyanoimidazole compounds | ISHIHARA SANGYO KAISHA LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
| US-4275213-A | Isoxazolyl derivatives of 9α,11α-epoxy imino-9,11,15-trideoxy-PGF-type compounds | THE UPJOHN COMPANY (US) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSD11B1 1019/4885NPC1 824/4885RAB9A 661/4885 |
| US-20160083358-A1 | COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN10, ATXN2, ATXN2L | HSD11B1 3849/4885NPC1 2715/4885RAB9A 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.